Back to Journals » Drug Design, Development and Therapy » Volume 5

Review

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

       
Total article views   HTML views PDF downloads Totals
36,973 Dovepress* 19,434+ 5,796 25,230
PubMed Central* 17,539 5,319 22,858
Totals 36,973 11,115 48,088
*Since 23 November 2011
+Since July 2016

View citations on PubMed Central and Google Scholar